MA-BATTERY-VENTURES
27.6.2024 13:01:33 CEST | Business Wire | Press release
Battery Ventures, a global, technology-focused investment firm, today announced six new internal promotions across three offices, including the elevation of Satoshi Harris-Koizumi to partner and Collier Searle to principal.
Harris-Koizumi is based in New York and focuses on later-stage and majority software investments, mainly in the U.S. Since joining Battery 12 years ago, he has supported technology companies transforming industries ranging from hospitality to manufacturing to engineering and supply chain, among others.
Specifically, Harris-Koizumi has worked with exited Battery software companies Cambrio (a CAD/CAM specialist, acquired by Sandvik); HighJump (supply-chain tech, acquired by Accellos); Mendix (low-code platform technology, acquired by Siemens); and Olo (restaurant-ordering software, NYSE: OLO). He is currently involved with Battery’s investments in product-content software company 1WorldSync; developer-tools software firm AdaCore; club/member-management software company Clubessential Holdings; restaurant-software provider Crunchtime; translation-software company Smartling; and engineering-design software firm Tech Soft 3D. Harris-Koizumi, known as Toshi, holds a BA in economics from Dartmouth.
Searle, also based in New York, joined Battery in 2020 and focuses on late-stage and buyout investments in Europe and the U.S. She is involved with Battery’s investments in ORTEC, a company based in the Netherlands which provides decision-support software and data-science capabilities, and Shiftmove, a Berlin-based company providing “mobility-management” solutions to enterprises. Battery formed Shiftmove last year after acquiring two complementary, European fleet-management companies, Vimcar and Avrios. Before Battery, Searle worked at Apax Partners and Bank of America Merrill Lynch. She holds a BA in philosophy and political science from Middlebury.
“We are extremely excited to promote Toshi to partner and Collier to principal,” said Morad Elhafed, a Battery general partner who works closely with both investors. “Toshi has distinguished himself both by sourcing key deals for the firm—including Cambrio, Clubessential, Mendix and Tech Soft—and, later, serving as a trusted advisor to our portfolio executives and helping their companies scale. Similarly, Collier has done outstanding sourcing and advisory work, particularly as we increase our buyout activity in Europe. We are excited for both of them to continue their careers at Battery and add more value to the firm as we move into our fifth decade of investing.”
Battery also named two new vice presidents, Max Jessen and Stefan Momic, and two new associates, Jack McGuinness and Grace Hermes. Jessen and Momic are both based in Boston and work in Battery’s growing industrial technology and life-science tools practice. McGuinness, based in London, also focuses on industrial technology and life-science tools, while Hermes works in Battery’s New York office and focuses on later-stage software investments.
Earlier this year, Battery also announced the promotions of Aaron Neil to vice president and Luis-Luca de Haas to associate. In addition, Matt Penney was promoted to partner, information technology.
Battery Ventures provides investment advisory services solely to privately offered funds. Battery Ventures neither solicits nor makes its services available to the public or other advisory clients. For more information about Battery Ventures’ potential financing capabilities for prospective portfolio companies, please refer to our website. For a complete list of portfolio companies, please click here.
About Battery
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, consumer tech, healthcare IT and industrial technology and life-science tools. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from offices in Boston, San Francisco, Menlo Park, New York, London, and Tel Aviv. Follow the firm on X @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627095034/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom